Evidence map›Paper›PMID 40572178›Full record

ReviewMicroorganisms2025

The Effects of Fecal Microbial Transplantation on the Symptoms in Autism Spectrum Disorder, Gut Microbiota and Metabolites: A Scoping Review.

Ignazio Maniscalco, Piotr Bartochowski, Vittoria Priori, Sidonia Paula Iancau, Michele De Francesco, Marco Innamorati, Natalia Jagodzinska, Giancarlo Giupponi, Luca Masucci, Andreas Conca and 1 more

Abstract readReview
In one paragraph

Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ignazio ManiscalcoDepartment of Psychiatry, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical, 39100 Bolzano, Italy.
Piotr BartochowskiBC2M, Faculty of Pharmacy, University of Montpellier, 34090 Montpellier, France.ORCID 0009-0006-5496-9556
Vittoria PrioriDepartment of Psychiatry, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical, 39100 Bolzano, Italy.
Sidonia Paula IancauResidence School in Psychiatry, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, 00185 Rome, Italy.ORCID 0009-0006-4051-2598
Michele De FrancescoDepartment of Psychiatry, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical, 39100 Bolzano, Italy.
Marco InnamoratiDepartment of Health and Life Sciences, European University of Rome, 00163 Roma, Italy.ORCID 0000-0003-1389-2290
Natalia JagodzinskaSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 1TN, UK.
Giancarlo GiupponiDepartment of Psychiatry, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical, 39100 Bolzano, Italy.
Luca MasucciMicrobiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Medicine, 00168 Roma, Italy.ORCID 0000-0002-8358-6726
Andreas ConcaDepartment of Psychiatry, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical, 39100 Bolzano, Italy.
Magdalena MroczekDepartment of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-8731-0540

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bilateral interaction between the brain and the gut has recently been on the spectrum of researchers' interests, including complex neural, endocrinological, and immunological signaling pathways. The first case reports and clinical studies have already reported that delivering microbes through fecal microbial transplantation (FMT) may alleviate symptoms of psychiatric disorders. Therefore, modifying the gut microbiota through FMT holds promise as a potential treatment for psychiatric diseases. This scoping review assessed studies from PubMed related to FMT in autism spectrum disorder and attention deficit hyperactivity disorder. The evaluation included nine clinical studies and case reports. The beneficial and persistent effect on the autism spectrum disorder (ASD) symptoms has been reported. Also, an increased microflora diversity and altered levels of neurometabolites in serum were identified, albeit with a tendency to return to baseline over time. The microbiome-gut-brain axis could provide new targets for preventing and treating psychiatric disorders. However, a recent large randomized clinical trial has shed light on the previously collected data and suggested a possible contribution of the placebo effect. This highlights the necessity of large randomized double-blind studies to reliably assess the effect of FMT in ASD.

Indexed as

ASDautism spectrum disordersfecal microbial transplantationFMTmicrobiota

Identifiers

PMID40572178
PMCPMC12195398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.